Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label …
…, CM Korse, RJ van Klaveren, FMNH Schramel… - The Lancet …, 2013 - thelancet.com
Background Standard chemotherapy does not lead to long-term survival in patients with
malignant pleural mesothelioma. Malignant pleural mesothelioma is strongly dependent on …
malignant pleural mesothelioma. Malignant pleural mesothelioma is strongly dependent on …
[HTML][HTML] Real-world outcomes versus clinical trial results of immunotherapy in stage IV non-small cell lung cancer (NSCLC) in the Netherlands
…, M Tonn, BJM Peters, FMNH Schramel… - Scientific Reports, 2021 - nature.com
This study aims to assess how clinical outcomes of immunotherapy in real-world (effectiveness)
correspond to outcomes in clinical trials (efficacy) and to look into factors that might …
correspond to outcomes in clinical trials (efficacy) and to look into factors that might …
[HTML][HTML] Decision support systems for incurable non-small cell lung cancer: a systematic review
…, EG Engelhardt, JJ Tamminga, FMNH Schramel… - BMC medical informatics …, 2017 - Springer
Background Individually tailored cancer treatment is essential to ensure optimal treatment
and resource use. Treatments for incurable metastatic non-small cell lung cancer (NSCLC) …
and resource use. Treatments for incurable metastatic non-small cell lung cancer (NSCLC) …
Videothoracoscopic appearance of first and recurrent pneumothorax
JP Janssen, FMNH Schramel, TG Sutedja, MA Cuesta… - Chest, 1995 - Elsevier
Study objective Comparison of the videothoracoscopic appearance of first and recurrent
pneumothorax, and assessment of a relation between endoscopic appearance and recurrence …
pneumothorax, and assessment of a relation between endoscopic appearance and recurrence …
Atmospheric pressure changes and outdoor temperature changes in relation to spontaneous pneumothorax
HJM Smit, WL Devillé, FMNH Schramel, AJM Schreurs… - Chest, 1999 - Elsevier
Study aims To examine the influence of atmospheric pressure (AP) and temperature changes
on the incidence of idiopathic spontaneous pneumothorax (SP). Methods From December …
on the incidence of idiopathic spontaneous pneumothorax (SP). Methods From December …
Systematic evaluation of the efficacy–effectiveness gap of systemic treatments in metastatic nonsmall cell lung cancer
…, BJM Peters, FMNH Schramel… - European …, 2018 - Eur Respiratory Soc
The divergence between clinical trial results and real-world outcomes is largely unknown for
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …
many cancer types. The present study aims overall to assess the efficacy–effectiveness gap …
Isolated lung perfusion with melphalan for resectable lung metastases: a phase I clinical trial
…, MJJH Grootenboers, FMNH Schramel… - The Annals of Thoracic …, 2004 - Elsevier
… with MN combined with pulmonary metastasectomy is feasible. Dose-limiting toxicity occurred
at a dose of 60 mg of MN at 37C, and the maximum tolerated dose was set at 45 mg of MN …
at a dose of 60 mg of MN at 37C, and the maximum tolerated dose was set at 45 mg of MN …
Evaluation of serum biomarker CEA and Ca-125 as immunotherapy response predictors in metastatic non-small cell lung cancer
…, BJM Peters, H Kelder, FMNH Schramel - Anticancer …, 2021 - ar.iiarjournals.org
Background/Aim: Treatment options for advanced non-small cell lung cancer (NSCLC) include
immunotherapy. Elevated carcinoembryonic antigen (CEA) and cancer antigen 125 (Ca-…
immunotherapy. Elevated carcinoembryonic antigen (CEA) and cancer antigen 125 (Ca-…
Clinical outcomes in early-stage NSCLC treated with stereotactic body radiotherapy versus surgical resection
…, M Van Vulpen, FMNH Schramel - Anticancer …, 2015 - ar.iiarjournals.org
Background: Surgical resection is the treatment of first choice for patients with stage I-II non-small
cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been …
cell lung cancer (NSCLC). However, stereotactic body radiotherapy (SBRT) has been …
[HTML][HTML] Phase II multicenter clinical trial of pulmonary metastasectomy and isolated lung perfusion with melphalan in patients with resectable lung metastases
…, J Braun, H Gelderblom, FMNH Schramel… - Journal of thoracic …, 2014 - Elsevier
Introduction The 5-year overall survival rate of patients undergoing complete surgical resection
of pulmonary metastases (PM) from colorectal cancer (CRC) and sarcoma remains low (…
of pulmonary metastases (PM) from colorectal cancer (CRC) and sarcoma remains low (…